Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 33,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Not applicable Interventional

Adjunctive Bright Light Therapy for Opioid Use Disorder

NCT05459922
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Wearable bright light therapy device, Wearable placebo light therapy device
Device
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 4 Interventional

Electroencephalography (EEG) Biomarkers of Response in Depression

NCT00759122
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
venlafaxine (Effexor), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 1 Interventional

The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream

NCT01883102
View directory record Official record
Conditions
Pain
Interventions
Capsaicin 0.1%, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
39 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

NCT00099853
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, pioglitazone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 3, 2026, 4:03 PM EST
Completed Not applicable Interventional Results available

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

NCT00560937
View directory record Official record
Conditions
Schizophrenia
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Nov 3, 2026, 4:03 PM EST
Withdrawn Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

NCT04306237
View directory record Official record
Conditions
Refractory Angina
Interventions
IMB-1018972, Placebo oral tablet
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 2 Interventional

The Effects of Vitamin D and Bone Loss in Parkinson's Disease

NCT00907972
View directory record Official record
Conditions
Parkinson Disease
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 3, 2026, 4:03 PM EST
Terminated Phase 4 Interventional Results available

Effect of Ketamine on Postoperative Clinical Outcomes

NCT01365195
View directory record Official record
Conditions
Colorectal Surgery
Interventions
Placebo, Ketamine high-dose, Ketamine low-dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 3, 2026, 4:03 PM EST
Terminated Not applicable Interventional

Oxandrolone Rotator Cuff Trial

NCT03091075
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Oxandrolone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
40 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT02607930
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 3, 2026, 4:03 PM EST
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
149
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Nov 3, 2026, 4:03 PM EST
Completed Not applicable Interventional Results available

Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)

NCT02959307
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Transcranial Light Therapy, Sham Transcranial Light Therapy
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Nov 3, 2026, 4:03 PM EST
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Nov 3, 2026, 4:03 PM EST
Recruiting Phase 2 Interventional

A Trial of Varenicline for E-cigarette Cessation

NCT07040566
View directory record Official record
Conditions
E-cigarette Use, Vaping, Nicotine Dependence
Interventions
Varenicline 1mg BID, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
New Haven, Connecticut • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 3, 2026, 4:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Covid-19 Messaging to Underserved Communities - 2nd Experiment

NCT04502056
View directory record Official record
Conditions
Covid19
Interventions
Acknowledgement Racial Injustice AMA, African American Sender Acknowledgement, African American Sender in Informational Videos., Racial Inequality Highlighted, AMA Acknowledgement Drug Pricing, White Sender in Acknowledgement, White Sender in Informational Videos, No Racial Inequality Highlighting, Placebo videos
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
20,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Nov 3, 2026, 4:03 PM EST
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

NCT00671502
View directory record Official record
Conditions
Lower Back Pain
Interventions
Carisoprodol SR, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Nov 3, 2026, 4:03 PM EST
Terminated Phase 2 Interventional Results available

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

NCT03938545
View directory record Official record
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Nov 3, 2026, 4:03 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07654972
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY4174794, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 4:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

NCT03815695
View directory record Official record
Conditions
Healthy Volunteers, Sickle Cell Disease
Interventions
FT-4202/Placebo
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Nov 3, 2026, 4:03 PM EST